Bladder urothelial carcinoma cells

Bladder urothelial carcinoma cells are the transformed epithelial cells lining the bladder that give rise to urothelial carcinoma, accounting for over 90% of bladder cancers and exhibiting high molecular and histological heterogeneity. These cells often harbor mutations in key genes like TP53 (common in invasive disease), FGFR3 (activating in luminal subtypes), and RB1, driving uncontrolled proliferation, invasion into the muscularis propria, and metastasis. Molecular subtypes include luminal (GATA3/KRT20-positive, FGFR-driven, better prognosis), basal/squamous (KRT5/6/p63-positive, aggressive but cisplatin-responsive), neuronal, and stroma-rich, influencing treatment selection. Immune profiling reveals "hot" subtypes with T-cell infiltration (high CD8A/CCL4) responsive to checkpoint inhibitors, while "cold" subtypes show exclusion via pathways like desmosome signaling or neutrophils, limiting immunotherapy efficacy. Therapies target these alterations, such as erdafitinib for FGFR3 mutations or platinum chemotherapy for basal tumors, but challenges persist due to variant-specific resistance (e.g., plasmacytoid with CDH1 loss) and high recurrence rates. Overall, these cells represent a complex disease entity where precision oncology relies on subtyping for optimal outcomes.

Other names

Urothelial carcinoma cellstransitional cell carcinoma cellsbladder cancer cells

FGFR inhibition (blocks activating FGFR3 mutations in luminal subtype), platinum-DNA crosslinking (exploits TP53/RB1 mutations in basal/squamous for chemosensitivity), PD-1/PD-L1 blockade (enhances T-cell response in hot/immune-inflamed subtypes), CDK4/6 inhibition (targets p53/cell cycle pathway)